Page 340 - Binder2

In the edible biologics world, you don’t need to own the
factory to make the drug.

You need the know-how, the gene, and the greenhouse.

That’s not just a cost reduction.
That’s a shift in power—from concentrated, capital-
intensive monopolies to agile, replicable networks.

And it signals the arrival of something long overdue in
biopharma:

A system that doesn’t break when one piece fails.
Instead, it flexes, adapts, and keeps producing.

4. It Doesn't Just Change the Process—It Changes the
Power Structure

In the pharmaceutical world, manufacturing isn't just
operational—it's strategic. The ability to produce complex
biologics in highly specialized, capital-intensive facilities
creates a power dynamic that shapes the entire ecosystem:

● Payers become dependent on a handful of
suppliers.
● Regulators defer to established players with proven
infrastructure.
● Smaller competitors are locked out by sheer
capital requirements.
● Governments must negotiate access rather than
build independence.

This isn’t a flaw in the system—it is the system. The
fortress isn’t just made of patents. It’s made of stainless

338